Prostate cancer in patients with metabolic syndrome is associated with low grade gleason score when diagnosed on biopsy

Korean Journal of Urology

Volumn 53, Issue 9, 2012, Pages 593-597

  Jeon, Kyoung Pil ^a   Jeong, Tae Yoong ^a   Lee, Seo Yeon ^a   Hwang, Sang Won ^a   Shin, Joong Hui ^a   Kim, Dong Suk ^a  

^a Kwandong University College of Medicine   (South Korea)

Author keywords

Biopsy; Metabolic syndrome; Prostatic neoplasms

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

AGED; ARTICLE; BIOPSY DEVICE; BIOPSY NEEDLE; BODY MASS; CANCER DIAGNOSIS; CANCER RISK; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; GLEASON SCORE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORGAN SIZE; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; WAIST CIRCUMFERENCE;

EID: 84867028812     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2012.53.9.593     Document Type: Article

References (25)

1. Ministry of Health and Welfare, Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2009. Goyang: Ministry of Health and Welfare, Korea Central Cancer Registry, National Cancer Center; 2011.
2. Kirby MG, Wagg A, Cardozo L, Chapple C, Castro-Diaz D, de Ridder D, et al. Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn 2010;29:1360-4.
3. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011;9:48.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
5. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-43.
6. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:1646-50.
7. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002;3:303-8.
8. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is asso ciated with reduced risk of prostate cancer. Am J Epidemiol 2006;164:1094-102.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
10. Chung HW, Kim DJ, Jin HD, Choi SH, Ahn CW, Cha BS, et al. Prevalence of metabolic syndrome according to the new criteria for obesity. J Korean Diabetes Assoc 2002;26:431-42.
11. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004;266:37-56.
12. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
13. Lee SE, Hong SK, Park HZ, Chang JS, Yoon CY, Byun SS, et al. Higher body mass index is associated with lower risk of prostate cancer detection via multi (≥12)-core prostate biopsy in Korean men. Urology 2010;76:1063-6.
14. Freedland SJ, Terris MK, Platz EA, Presti JC Jr. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology 2005;66:108-13.
15. de Santana IA, Moura GS, Vieira NF, Cipolotti R. Metabolic syndrome in patients with prostate cancer. Sao Paulo Med J 2008;126:274-8.
16. Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006;17:5-9.
17. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004;13: 47-55.
18. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A, et al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011 Feb [Epub]. http://dx.doi.org/10.1002/pros.21364.
19. Han BK, Choi WS, Yu JH, Han JH, Chang IH, Jeong SJ, et al. The characteristics of prostate cancer with metabolic syndrome in Korean men. Korean J Urol 2007;48:585-91.
20. Moreira DM, Anderson T, Gerber L, Thomas JA, Banez LL, McKeever MG, et al. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control 2011;22:977-83.
21. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44.
22. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
23. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
24. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560-70.
25. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14:1262-9.